EGFR and neoplasm: mTKIs are not only directed against the VEGF/VEGFR pathway but also inhibit various cellular processes involved in tumor growth and angiogenesis (e.g., platelet-derived growth factor receptor, fibroblast growth factor receptor [FGFR], epidermal growth factor receptor [EGFR], and c-mesenchymal–epithelial transition [cMET]).5 The toxicity of targeted drugs depends on the specific target of the drug itself, and for this reason, adverse events are referred to as class effects.